<DOC>
	<DOCNO>NCT02140047</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety MT-2301 co-administered DPT-IPV use ActHIB® control healthy infant .</brief_summary>
	<brief_title>Exploratory Clinical Study MT-2301</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant age ≥2 &lt; 7 month first vaccination study drug Written inform consent obtain legal guardian ( parent ) With obvious pyrexia ( axillary temperature 37.5ºC high ) vaccination study drug With know serious acute disease With know underlying disease cardiovascular disease , renal disease , hepatic disease , blood dyscrasia , respiratory disease With past diagnosis immunodeficiency currently immunosuppressive treatment History anaphylaxis due food pharmaceutical With experience Hib infection , diphtheria , pertussis , tetanus , acute poliomyelitis With experience Hib vaccination , administration vaccine include either diphtheria , pertussis , tetanus , polio constituent History convulsion Administered live vaccine within 27 day first vaccination study drug , inactivate vaccine toxoid within 6 day vaccination Administered transfusion , immunosuppressant ( exclude drug external use ) , immunoglobulin formulation Administered corticosteroid 2 mg/kg per day prednisolone ( exclude drug external use ) continuously 1 week Participated study within 12 week obtain consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Haemophilus influenza type b</keyword>
	<keyword>Hib</keyword>
</DOC>